BioSpace News Archive

Smart Pills market analysis report is produced in such a way that it works toward making the reports easier to read, and easier for managers to absorb the information they need to make decisions.

Healthcare Integration Solutions Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Healthcare Integration Solutions market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Respiratory Care Devices Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Respiratory Care Devices market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi’s pipeline for Greater China.

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401).

BioArctic AB’s partner Eisai announced that the U.S. Food and Drug Administration has accepted the Biologics License Application under the accelerated approval pathway for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD, with confirmed presence of amyloid pathology in the brain.

PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that their latest research results were presented at the BIO International Convention in June.

A recent report provides crucial insights along with application based and forecast information in the Global Basic Infusion Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market.

The global Equine Pharmaceuticals and Supplements market size is estimated to be worth US$ 1148 million in 2021 and is forecast to a readjusted size of US$ 1568 million by 2030 with a CAGR of 4.5% during the forecast period 2022-2030.